S&P 500   4,584.80 (+0.40%)
DOW   35,854.74 (+0.32%)
QQQ   379.73 (+0.48%)
AAPL   149.38 (+0.50%)
MSFT   309.66 (+0.50%)
FB   314.59 (-4.29%)
GOOGL   2,784.06 (+1.28%)
TSLA   1,032.40 (+0.74%)
AMZN   3,382.97 (+1.89%)
NVDA   247.07 (+6.65%)
BABA   170.16 (-3.41%)
NIO   40.93 (-0.82%)
CGC   13.20 (-2.73%)
GE   107.78 (+2.36%)
AMD   123.59 (+1.01%)
MU   69.01 (+0.36%)
T   25.42 (-0.86%)
F   15.92 (-0.50%)
ACB   7.08 (-1.39%)
DIS   171.97 (-0.02%)
PFE   43.59 (+1.02%)
BA   209.91 (-1.39%)
AMC   36.54 (-0.79%)
S&P 500   4,584.80 (+0.40%)
DOW   35,854.74 (+0.32%)
QQQ   379.73 (+0.48%)
AAPL   149.38 (+0.50%)
MSFT   309.66 (+0.50%)
FB   314.59 (-4.29%)
GOOGL   2,784.06 (+1.28%)
TSLA   1,032.40 (+0.74%)
AMZN   3,382.97 (+1.89%)
NVDA   247.07 (+6.65%)
BABA   170.16 (-3.41%)
NIO   40.93 (-0.82%)
CGC   13.20 (-2.73%)
GE   107.78 (+2.36%)
AMD   123.59 (+1.01%)
MU   69.01 (+0.36%)
T   25.42 (-0.86%)
F   15.92 (-0.50%)
ACB   7.08 (-1.39%)
DIS   171.97 (-0.02%)
PFE   43.59 (+1.02%)
BA   209.91 (-1.39%)
AMC   36.54 (-0.79%)
S&P 500   4,584.80 (+0.40%)
DOW   35,854.74 (+0.32%)
QQQ   379.73 (+0.48%)
AAPL   149.38 (+0.50%)
MSFT   309.66 (+0.50%)
FB   314.59 (-4.29%)
GOOGL   2,784.06 (+1.28%)
TSLA   1,032.40 (+0.74%)
AMZN   3,382.97 (+1.89%)
NVDA   247.07 (+6.65%)
BABA   170.16 (-3.41%)
NIO   40.93 (-0.82%)
CGC   13.20 (-2.73%)
GE   107.78 (+2.36%)
AMD   123.59 (+1.01%)
MU   69.01 (+0.36%)
T   25.42 (-0.86%)
F   15.92 (-0.50%)
ACB   7.08 (-1.39%)
DIS   171.97 (-0.02%)
PFE   43.59 (+1.02%)
BA   209.91 (-1.39%)
AMC   36.54 (-0.79%)
S&P 500   4,584.80 (+0.40%)
DOW   35,854.74 (+0.32%)
QQQ   379.73 (+0.48%)
AAPL   149.38 (+0.50%)
MSFT   309.66 (+0.50%)
FB   314.59 (-4.29%)
GOOGL   2,784.06 (+1.28%)
TSLA   1,032.40 (+0.74%)
AMZN   3,382.97 (+1.89%)
NVDA   247.07 (+6.65%)
BABA   170.16 (-3.41%)
NIO   40.93 (-0.82%)
CGC   13.20 (-2.73%)
GE   107.78 (+2.36%)
AMD   123.59 (+1.01%)
MU   69.01 (+0.36%)
T   25.42 (-0.86%)
F   15.92 (-0.50%)
ACB   7.08 (-1.39%)
DIS   171.97 (-0.02%)
PFE   43.59 (+1.02%)
BA   209.91 (-1.39%)
AMC   36.54 (-0.79%)
NASDAQ:RGNX

REGENXBIO Stock Forecast, Price & News

$36.26
-0.29 (-0.79 %)
(As of 10/26/2021 03:15 PM ET)
Add
Compare
Today's Range
$36.17
$37.37
50-Day Range
$29.09
$45.68
52-Week Range
$27.02
$50.26
Volume8,155 shs
Average Volume417,433 shs
Market Capitalization$1.54 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.21
30 days | 90 days | 365 days | Advanced Chart
Receive RGNX News and Ratings via Email

Sign-up to receive the latest news and ratings for REGENXBIO and its competitors with MarketBeat's FREE daily newsletter.


REGENXBIO logo

About REGENXBIO

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors; and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RGNX
Employees
306
Year Founded
N/A

Sales & Book Value

Annual Sales
$154.57 million
Book Value
$10.10 per share

Profitability

Net Income
$-111.25 million

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$1.54 billion
Next Earnings Date
11/3/2021 (Estimated)
Optionable
Optionable

MarketRank

Overall MarketRank

2.49 out of 5 stars

Medical Sector

127th out of 1,363 stocks

Biological Products, Except Diagnostic Industry

17th out of 196 stocks

Analyst Opinion: 4.4Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -












REGENXBIO (NASDAQ:RGNX) Frequently Asked Questions

Is REGENXBIO a buy right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for REGENXBIO in the last year. There are currently 2 hold ratings, 5 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" REGENXBIO stock.
View analyst ratings for REGENXBIO
or view top-rated stocks.

What stocks does MarketBeat like better than REGENXBIO?

Wall Street analysts have given REGENXBIO a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but REGENXBIO wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is REGENXBIO's next earnings date?

REGENXBIO is scheduled to release its next quarterly earnings announcement on Wednesday, November 3rd 2021.
View our earnings forecast for REGENXBIO
.

How were REGENXBIO's earnings last quarter?

REGENXBIO Inc. (NASDAQ:RGNX) posted its quarterly earnings results on Monday, August, 9th. The biotechnology company reported ($1.36) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($1.08) by $0.28. The biotechnology company had revenue of $22.04 million for the quarter, compared to the consensus estimate of $21.17 million. REGENXBIO had a negative trailing twelve-month return on equity of 31.31% and a negative net margin of 90.05%. The business's quarterly revenue was up 33.0% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.91) earnings per share.
View REGENXBIO's earnings history
.

How has REGENXBIO's stock been impacted by COVID-19 (Coronavirus)?

REGENXBIO's stock was trading at $32.89 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, RGNX stock has increased by 10.9% and is now trading at $36.47.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for RGNX?

8 equities research analysts have issued twelve-month price objectives for REGENXBIO's shares. Their forecasts range from $17.00 to $100.00. On average, they anticipate REGENXBIO's stock price to reach $58.75 in the next year. This suggests a possible upside of 61.1% from the stock's current price.
View analysts' price targets for REGENXBIO
or view top-rated stocks among Wall Street analysts.

Who are REGENXBIO's key executives?

REGENXBIO's management team includes the following people:
  • Kenneth T. Mills, President, Chief Executive Officer & Director
  • Curran M. Simpson, SVP, Chief Operations & Technology Officer
  • Vit Vasista, Chief Financial Officer & Senior Vice President
  • Olivier Danos, Chief Scientific Officer & Senior Vice President
  • Stephen Pakola, Chief Medical Officer & Senior Vice President

What is Ken Mills' approval rating as REGENXBIO's CEO?

3 employees have rated REGENXBIO CEO Ken Mills on Glassdoor.com. Ken Mills has an approval rating of 68% among REGENXBIO's employees.

What other stocks do shareholders of REGENXBIO own?

Based on aggregate information from My MarketBeat watchlists, some companies that other REGENXBIO investors own include AbbVie (ABBV), Micron Technology (MU), NVIDIA (NVDA), Voyager Therapeutics (VYGR), Amarin (AMRN), CRISPR Therapeutics (CRSP), Pfizer (PFE), QUALCOMM (QCOM), Gilead Sciences (GILD) and Square (SQ).

What is REGENXBIO's stock symbol?

REGENXBIO trades on the NASDAQ under the ticker symbol "RGNX."

Who are REGENXBIO's major shareholders?

REGENXBIO's stock is owned by a variety of retail and institutional investors. Top institutional investors include Assenagon Asset Management S.A. (0.32%), DekaBank Deutsche Girozentrale (0.08%), Liberty One Investment Management LLC (0.07%), State of Alaska Department of Revenue (0.06%), Louisiana State Employees Retirement System (0.04%) and Strs Ohio (0.01%). Company insiders that own REGENXBIO stock include Allan M Fox, Curran Simpson, Donald J Hayden Jr, Kenneth T Mills, Kenneth T Mills, Patrick J Christmas, Vittal Vasista and WR Stephens, Iii 2012 Trust.
View institutional ownership trends for REGENXBIO
.

Which institutional investors are selling REGENXBIO stock?

RGNX stock was sold by a variety of institutional investors in the last quarter, including DekaBank Deutsche Girozentrale. Company insiders that have sold REGENXBIO company stock in the last year include Allan M Fox, Curran Simpson, Kenneth T Mills, Patrick J Christmas, Vittal Vasista, and WR Stephens, Iii 2012 Trust.
View insider buying and selling activity for REGENXBIO
or view top insider-selling stocks.

Which institutional investors are buying REGENXBIO stock?

RGNX stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Everence Capital Management Inc., State of Alaska Department of Revenue, Louisiana State Employees Retirement System, Strs Ohio, Liberty One Investment Management LLC, and Koshinski Asset Management Inc..
View insider buying and selling activity for REGENXBIO
or or view top insider-buying stocks.

How do I buy shares of REGENXBIO?

Shares of RGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is REGENXBIO's stock price today?

One share of RGNX stock can currently be purchased for approximately $36.47.

How much money does REGENXBIO make?

REGENXBIO has a market capitalization of $1.55 billion and generates $154.57 million in revenue each year. The biotechnology company earns $-111.25 million in net income (profit) each year or ($2.98) on an earnings per share basis.

How many employees does REGENXBIO have?

REGENXBIO employs 306 workers across the globe.

What is REGENXBIO's official website?

The official website for REGENXBIO is www.regenxbio.com.

Where are REGENXBIO's headquarters?

How can I contact REGENXBIO?

REGENXBIO's mailing address is 9600 BLACKWELL ROAD SUITE 210, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at (240) 552-8181 or via email at [email protected].


This page was last updated on 10/26/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.